

treat infections now and in the future. The Centers for Disease Control and Prevention (CDC) works on the implementation, innovation and education of this program.^[1]

CONCLUSION:

The large number of QIDP designations granted since 2012 indicates that the new antibacterial program is frequently utilized by sponsors developing antibacterial drugs. Pharmaceutical companies have started to show increased interest in the antibacterial research arena, due to new laws and acts such as GAIN and LPAD helps them in antibacterial drug development by incentivizing and providing new pathways for faster reviewing process.

ACKNOWLEDGEMENT:

The authors thank JSS Academy of Higher Education and Research and JSS College of Pharmacy, Mysuru for providing the necessary facilities for carrying out this work.

REFERENCES:

- [1] FDA Guidance on “Generating antibiotic incentives now”. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at <https://www.fda.gov/media/110982/download>
- [2] Bax R¹, Green S². J Antimicrob Chemother 2015 May; 70(5):1281-4. doi: 10.1093/jac/dku572. Epub 2015 Jan 28
- [3] Helen.W.Boucher et.al Clin Infect Dis. 2013 Jun 15; 56(12): 1685–1694. Published online 2013 Apr 17. doi: 10.1093/cid/cit152
- [4] FDA Draft Guidance on “Qualified Infectious Disease Product Designation: Questions and Answers. Guidance for Industry”. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at <https://www.fda.gov/media/111091/download>
- [5] FDA Draft Guidance on “Limited Population Pathway for Antibacterial and Antifungal Drugs”. Available at <https://www.fda.gov/files/drugs/published/Limited-Population-Pathway-for-Antibacterial-and-Antifungal-Drugs-Guidance-for-Industry.pdf>
- [6] John H. Rex. New pathways for antibiotics, International Federation of Pharmaceutical Manufacturers and Association – 30/04/2015. Available at: <http://drive-ab.eu/wp-content/uploads/2014/09/Rex-JH-2015-04-30-IFPMA-New-pathways-for-antibiotics-v1.3.pdf>